Trials / Withdrawn
WithdrawnNCT01757262
A Clinical Study of Safety and P2Y12 Receptor Inhibition Effects of Ticagrelor and Clopidogrel in Vietnamese Patient
Safety and P2Y12 Receptor Inhibition Effects of Ticagrelor and Clopidogrel in Vietnamese Patients With Coronary Heart Disease: A Randomized, Open Label, Crossover Study
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Study in Vietnamese Patients with Coronary Heart Disease to investigate safety and P2Y12 Receptor Inhibition Effects of Ticagrelor and Clopidogrel
Detailed description
Safety and P2Y12 Receptor Inhibition Effects of Ticagrelor and Clopidogrel in Vietnamese Patients with Coronary Heart Disease: A Randomized, Open Label, Crossover Study
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 90 mg Ticagrelor | Morning and Evening dose for 5 days |
| DRUG | 75mg Clopidogrel | Morning dose for 5 days |
Timeline
- Start date
- 2013-01-01
- Primary completion
- 2013-04-01
- Completion
- 2013-04-01
- First posted
- 2012-12-28
- Last updated
- 2013-05-13
Source: ClinicalTrials.gov record NCT01757262. Inclusion in this directory is not an endorsement.